Cohance Lifesciences Limited Stock Price Today (NSE: COHANCE)
Fundamental Score
Cohance Lifesciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cohance Lifesciences Limited share price today is ₹432.95, up +2.21% on NSE/BSE as of 16 September 2026. Cohance Lifesciences Limited (COHANCE) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹16.56K (Cr). The 52-week high for COHANCE share price is ₹996.00 and the 52-week low is ₹266.70. At a P/E ratio of 155.74x, COHANCE is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 6.39% and a debt-to-equity ratio of 0.04.
Cohance Lifesciences Limited Share Price Chart — NSE/BSE Historical Performance
Cohance Lifesciences Limited share price chart: 1.03% return over the past month. 52-week high ₹996.00, 52-week low ₹266.70.
Cohance Lifesciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹425.60 | ₹434.60 | ₹416.20 | ₹432.95 | 3.20L (Cr) | |
| ₹440.10 | ₹443.15 | ₹421.35 | ₹423.60 | 3.84L (Cr) | |
| ₹445.20 | ₹445.20 | ₹434.15 | ₹440.20 | 4.68L (Cr) | |
| ₹443.35 | ₹453.30 | ₹440.70 | ₹445.30 | 12.42L (Cr) | |
| ₹453.85 | ₹455.20 | ₹436.25 | ₹443.35 | 14.16L (Cr) | |
| ₹451.80 | ₹460.50 | ₹448.10 | ₹451.60 | 18.33L (Cr) | |
| ₹450.00 | ₹458.20 | ₹443.50 | ₹449.55 | 8.46L (Cr) | |
| ₹463.30 | ₹470.00 | ₹453.60 | ₹456.60 | 5.73L (Cr) | |
| ₹462.00 | ₹464.75 | ₹457.80 | ₹460.85 | 5.40L (Cr) | |
| ₹460.00 | ₹469.60 | ₹452.20 | ₹458.30 | 4.17L (Cr) |
Cohance Lifesciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹458.60 | ₹476.50 | ₹416.20 | ₹432.95 | -5.59% | |
| ₹425.05 | ₹484.00 | ₹416.90 | ₹455.95 | +7.27% | |
| ₹456.50 | ₹473.70 | ₹411.00 | ₹425.05 | -6.89% | |
| ₹431.05 | ₹486.30 | ₹403.40 | ₹456.15 | +5.82% | |
| ₹487.00 | ₹505.00 | ₹391.05 | ₹431.50 | -11.40% | |
| ₹308.95 | ₹514.90 | ₹292.50 | ₹483.25 | +56.42% | |
| ₹295.00 | ₹312.90 | ₹266.70 | ₹301.45 | +2.19% | |
| ₹369.90 | ₹399.45 | ₹303.05 | ₹309.95 | -16.21% | |
| ₹528.95 | ₹531.35 | ₹368.40 | ₹381.30 | -27.91% | |
| ₹570.05 | ₹572.00 | ₹518.15 | ₹528.60 | -7.27% | |
| ₹753.40 | ₹760.80 | ₹556.35 | ₹564.40 | -25.09% | |
| ₹883.45 | ₹917.85 | ₹749.05 | ₹753.40 | -14.72% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Cohance Lifesciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cohance Lifesciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of COHANCE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (39.16%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (17.57% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.43)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1039.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (57.49%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 27.38%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (6.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.30%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 155.74x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (6.50x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-149.34%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-23.13%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-19.91% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-13.13% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Cohance Lifesciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Cohance Lifesciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Cohance Lifesciences LimitedCohance Lifesci...Selected✓ COHANCE • 543064 | 34.2/100 | ₹432.95₹433 | ₹16564.67₹16564.67 | 155.74Average 155.7 Average | 6.39%Poor 6.39% Poor | 6.30%Poor 6.30% Poor | 0.04Excellent 0.0 Excellent | -13.13%Poor -13.13% Poor | 17.57%Excellent 17.57% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Cohance Lifesciences Limited PE Ratio History
Historical price-to-earnings ratio for COHANCE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹10.45 | ₹528.60 | 50.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Cohance Lifesciences Limited Dividend History
Annual cash dividends paid by COHANCE — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹203.65 Cr |
| FY 2022 | ₹101.83 Cr |
| FY 2021 | ₹25.46 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Cohance Lifesciences Limited Quarterly Performance
Latest quarterly metrics for COHANCE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-23.13%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-149.34%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
17.57%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-13.13%
Compounded annual net profit growth over 5 years
Cohance Lifesciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for COHANCE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Cohance Lifesciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Cohance Lifesciences Limited (COHANCE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Cohance Lifesciences Limited
About COHANCE (Cohance Lifesciences Limited)
COHANCE LIFESCIENCES LTD is a dynamic pharmaceutical innovator, focused on the intricate dance between scientific discovery and efficient production. It navigates the complexities ...of drug development, specializing in the creation of building blocks for tomorrow's therapies. From initial research to large-scale manufacturing, the company is committed to precision and quality, serving as a trusted partner for pharmaceutical companies across the globe. COHANCE blends cutting-edge research with practical manufacturing expertise, playing a pivotal role in the intricate pharmaceutical supply chain. Its mission is to fuel advancements in healthcare by enabling the streamlined development and manufacturing of critical pharmaceutical components. COHANCE concentrates on the vital components that make medicines work, focusing on the development and manufacture of specialized chemical compounds. The company excels in the creation of Active Pharmaceutical Ingredients (APIs), the very heart of medications, along with advanced intermediates that serve as the stepping stones in their synthesis. COHANCE also manufactures specialty chemicals crucial for drug development, as well as formulated drugs that have proven their efficacy and are widely prescribed. By concentrating on core pharmaceutical elements, COHANCE empowers its clients to focus on innovation and distribution, confident in the quality and reliability of their source materials. COHANCE LIFESCIENCES LTD extends its reach beyond geographical boundaries, providing its specialized services and products to pharmaceutical companies in India, the United States, Europe, and other countries. COHANCE enables the quick and efficient development of life-saving pharmaceuticals by utilizing its worldwide network and state-of-the-art facilities. With a focus on quality control and regulatory compliance, COHANCE assures its clients that its products meet the highest standards. COHANCE is dedicated to advancing healthcare worldwide by providing vital components for the pharmaceutical sector with accuracy and dependability, from APIs and sophisticated intermediates to formulated drugs.
Company Details
Key Leadership
COHANCE Share Price: Frequently Asked Questions
What is the current share price of Cohance Lifesciences Limited?
Cohance Lifesciences Limited (COHANCE) trades at ₹432.95 on NSE and BSE. Market cap ₹16.56K (Cr). Educational data only.
What is the P/E ratio of Cohance Lifesciences Limited?
Cohance Lifesciences Limited has a P/E of 155.74x vs industry average 34.89x.
What is the Bull Run score for Cohance Lifesciences Limited?
Cohance Lifesciences Limited has a Bull Run score of 34.2/100 based on 25+ financial parameters.
Does Cohance Lifesciences Limited pay dividends?
Cohance Lifesciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Cohance Lifesciences Limited?
Cohance Lifesciences Limited has ROE of 6.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Cohance Lifesciences Limited?
Cohance Lifesciences Limited has debt-to-equity of 0.04.
Is Cohance Lifesciences Limited a good investment?
Bull Run gives Cohance Lifesciences Limited a score of 34.2/100. This is not investment advice — consult a SEBI-registered advisor.